Fierce BioBiotech
Kailera CEO 'knew we were in a good spot' before obesity biotech's record-breaking $625M IPO
Summary
Kailera Therapeutics appears to have set a new benchmark for biotech IPOs with an upsized $625 million offering to fund its pipeline of obesity therapies.
Kailera Therapeutics appears to have set a new benchmark for biotech IPOs with an upsized $625 million offering to fund its pipeline of obesity therapies.